| Current Price | $109.49 | Mkt Cap | $193.5B |
|---|---|---|---|
| Open | $108.81 | P/E Ratio | 29.37 |
| Prev. Close | $109.49 | Div. (Yield) | $5.20 (4.7%) |
| Daily Range | $108.20 - $109.58 | Volume | 4,115 |
| 52-Wk Range | $79.11 - $121.53 | Avg. Daily Vol. | 8,063,418 |
| Current Price | $109.49 | Mkt Cap | $193.5B |
|---|---|---|---|
| Open | $108.81 | P/E Ratio | 29.37 |
| Prev. Close | $109.49 | Div. (Yield) | $5.20 (4.7%) |
| Daily Range | $108.20 - $109.58 | Volume | 4,115 |
| 52-Wk Range | $79.11 - $121.53 | Avg. Daily Vol. | 8,063,418 |
The best Bull and Bear pitches based on recency and number of recommendations.
Sold off due to patent cliff concerns and Hep C drug discounts. I believe this is an overreaction and the stock will recover. There is more in the pipeline than the P/E - 13 - would imply.
This mega-cap has made a big run since Express Scripts's announcement that it will take AbbVie's hep C treatment in lieu of Gilead's. Also, an amazing preponderance of CAPS bulls favor this stock beating the market from here -- very interesting. For… More
Read the most recent pitches from players about ABBV.
Recs
TMFkodyk123
(31.75)
Submitted: 7/26/2021 12:53:49 PM :
Start Price:
$116.31
NYSE:ABBV Score:
-9.47
Despite AbbVie's near-term headwinds relating to the upcoming loss of exclusivity of Humira in the U.S., the company boasts promising drugs in its oncology and immunology segments. Venclexta has 3 different indications that are anticipated to be approved by next year. In addition, the stock appears to be trading at a discount to fair value with an attractive 4.4% dividend yield.
Recs
Millions2021
(< 20)
Submitted: 7/11/2021 6:45:46 PM :
Start Price:
$114.14
NYSE:ABBV Score:
-8.80
Great growth.
Recs
cwardfs
(< 20)
Submitted: 3/5/2021 7:50:01 PM :
Start Price:
$102.29
NYSE:ABBV Score:
-11.42
This is my biopharmaceutical choice.
Find the members with the highest scoring picks in ABBV.
cooleyly (49.71) Score: +159.94
The Score Leader is the player with the highest score across all their picks in ABBV.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| armydave | 71.28 |
|
|
5Y | $23.26 | +370.73% | +210.78% | +159.94 | 0 Comment | |
| pirotta | < 20 | 1/10/2013 |
|
5Y | $23.26 | +370.73% | +210.78% | +159.94 | 0 Comment | |
| deliman723 | 63.13 | 1/10/2013 |
|
5Y | $23.26 | +370.73% | +210.78% | +159.94 | 0 Comment | |
| concealedweaponR | < 20 | 1/10/2013 |
|
5Y | $23.26 | +370.73% | +210.78% | +159.94 | 0 Comment | |
| drjohn432 | < 20 |
|
|
5Y | $23.26 | +370.73% | +210.78% | +159.94 | 0 Comment | |
|
valari25 | 97.84 |
|
|
5Y | $23.26 | +370.73% | +210.78% | +159.94 | 0 Comment |
|
|
GW1000 | 87.76 |
|
|
5Y | $23.26 | +370.73% | +210.78% | +159.94 | 0 Comment |
|
|
mattmmurphy | 69.15 | 1/10/2013 |
|
5Y | $23.26 | +370.73% | +210.78% | +159.94 | 0 Comment |
| cooleyly | 49.71 | 1/10/2013 |
|
5Y | $23.26 | +370.73% | +210.78% | +159.94 | 0 Comment | |
|
|
kinosternon | 96.97 | 1/9/2013 |
|
5Y | $23.37 | +368.59% | +212.22% | +156.37 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
